Connect with us

Nation

Judicial Watch: FDA Under Obama Paid For Fresh Fetal Body Parts To Create ‘humanized mice’

Published

on

MiceFinalshutterstock 210003694

A top government watchdog group obtained  165 pages of records from the Food and Drug Administration (FDA) revealing that the FDA under the Obama administration paid $96,370 for “fresh and never frozen” tissue from first and second trimester aborted fetuses to use in creating ‘humanized mice’ for ongoing research.”

The purchases included eight contracts signed “between 2012 and 2018” with the non-profit group Advanced Bioscience Resources (ABR) to acquire the baby body parts.

ABR was the subject of numerous past  criminal referrals issued by House and Senate committees, stated the watchdog. Lawmakers are also investigating whether Planned Parenthood “or any other entity was illegally profiting from the handling of fetal tissue from aborted babies,” the press release stated.

From The Judicial Watch Press Release:

Federal law regulates the purchase and acceptance of human fetal tissue for research purposes. It is unlawful to knowingly transfer fetal tissue for profit.

Judicial Watch filed the lawsuit in the United States District Court for the District of Columbia (Judicial Watch v. U.S. Department Health and Human Services (No. 1:19-cv-00876)) after HHS failed to respond adequately to a September 28, 2018, FOIA request seeking:

  1. All contracts and related documentation between FDA and Advanced Biosciences Resources (ABR) for the provision of human fetal tissue to be used in humanized mice research.
  2. All records reflecting the disbursement of funds to ABR for the provision of human fetal tissue to be used in humanized mice research.
  1. All guidelines and procedural documents provided to ABR by FDA relating to the acquisition and extraction of human fetal tissue for its provision to the FDA for humanized mice research.
  2. All communications between FDA officials and employees and representatives of ABR related to the provision by ABR to the FDA of human fetal tissue for the purpose of humanized mice research.

Records obtained by the conservative watchdog group reveal a June 28, 2017, email exchange with the subject line “FDA RFQ” (Request for Quotation) between a redacted FDA contract specialist and an ABR official named Ms. Larton.

The FDA official asks Larton, an ABR official, “I am tasked with the purchase of tissues suitable for HM [humanized mice] research. I would like to request a quote. Please review the Statement of Work and quote your pricing as outlined.” She then includes a table for 16 “Human Fetal Tissue – Liver”, 16 “Human Fetal Tissue – Thymus”, 16 HIV, HepA, HepB, HepC tests, and shipping and delivery. The Statement of Work notes:

The Division of Applied Regulatory Science (DARS) OCP/OTS/CDER is conducting a research program to evaluate the usefulness of humanized mice (HM) for regulatory purposes.

The HM are created by surgical implantation of human tissue into mice that have multiple genetic mutations that block the development of the mouse immune system at a very early stage. The absence of the mouse immune system allows the human tissues to grow and develop into functional human tissues. As part of this process DARS needs to repeatedly acquire the proper type of tissues. In order for the humanization to proceed correctly we need to obtain fetal tissue with a specific set of specialized characteristics.

For more on this story go to Judicial Watch.

You may like

Continue Reading

Nation

Health Industry Distributors’ Association: Supply Chain Delays ‘A Healthcare Issue’

Published

on

supply chain

The Health Industry Distributors’ Association (HIDA) released harrowing data stating “Transportation Delays Are A Healthcare Issue.” HIDA’s December release states, “research estimates that approximately 8,000-12,000 containers of critical medical supplies are delayed an average of up to 37 days throughout the transportation system.”

The statement continues, “The West Coast port with the greatest number of delayed medical containers are the Ports of Long Beach and Los Angeles. The most congested East Coast port is the Port of Savannah.”

An infographic is accompanied with the statement which breaks down the crisis further. 17 is the average number of days the shipments are delayed at the Port. There’s an 11 day average delay by rail, and a 9 day average delay by truck.

In those shipping containers, the infographic states 187,000 gowns, 360,000 syringes and 3.5 million surgical gloves are held. The ports with the most medical delayed supplies are Los Angeles/Long Beach, Savannah, New York/New Jersey, Charleston, Seattle, Oakland, Boston, Baltimore and Houston.

Axios reports under a “Why it matters” headline, that “Per their projections, medical supplies arriving at a U.S. port on Christmas Day won’t be delivered to hospitals and other care settings until February 2022.”

As a result, “that could delay critical supplies at a time when health care is already expected to most need them due to surges from Delta and Omicron.”

Additionally, “The supply chain problems can compound, starting with medical supplies languishing in U.S. ports for an average of 17 days, officials said.”

You may like

Continue Reading
Advertisement

Trending Now

Advertisement

Trending

Proudly Made In America | © 2022 M3 Media Management, LLC